Benefits of Amantadine in Patients With Coma State

Last updated: September 5, 2018
Sponsor: Dokuz Eylul University
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT03443037
265-SBKAEK
  • Ages 18-65
  • All Genders

Study Summary

The study was a single center observational-prospective study and approved by local ethics committee. Patients in coma state due to traumatic brain injury, cardiac arrest or ischemic stroke who are older than 18 years of age were included in the study. Patients who received amantadine 200mg/day for fourteen days according to ICU protocols decided by primary physician formed the amantadine group, and the rest of the subjects were included in the control group. All patients were evaluated for Glasgow Coma Score, JFK Coma Recovery Scale and Disability Rating Scale once a week for three months.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • ≥18 years, ≤ 65 years

  • GCS score ≤ 8

  • Coma state due to ischemic stroke, brain hemorhage, anoxic brain damage

Exclusion

Exclusion Criteria:

  • <18 years, > 65 years

  • Patients admitted to the critical care without diagnosis of coma state

  • Patients admitted to critical care with coma state that are not duo to ischemicstroke, brain hemorhage, anoxic brain damage

  • Metastatic malignant neoplazm

  • Congenital or acquired brain function problem (cerebral palsy, autism etc)

  • Patients with amantadine allergy

  • Progressive degenerative diseases (Alzheimer, Parkinson diseases etc)

Study Design

Total Participants: 56
Study Start date:
March 01, 2016
Estimated Completion Date:
July 01, 2019

Connect with a study center

  • Dokuz Eylul University

    Izmir,
    Turkey

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.